| Name | Title | Contact Details |
|---|
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
Aya Healthcare creates exceptional experiences – for their clinicians, their corporate employees and the healthcare facilities they serve. For healthcare facilities, Aya delivers a robust suite of software and services to manage the procurement of contingent labor. Aya’s platform provides access to one of the largest sources of contract clinicians in the country which improves efficiency, increases quality and reduces costs for healthcare systems. For travel nurses, Aya delivers the best experience in the industry and allows access to the widest base of travel assignments in the United States.
The Rothman Institute is affiliated with Hospitals consisting of state-of-the-art facilities befitting world-class orthopaedic centers. Everything, from clinical and surgical centers, a fully equipped imaging area (with the latest MRI equipment) and a physical therapy center, to a pain management area, an orthotic center and research laboratories, libraries and an educational center is all under one roof.
Cass Co. Human Services Coordinating Council is a Cassopolis, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.